A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-01-31
Target enrollment:
Participant gender:
Summary
Part 1 is the dose escalation of APG-115 in combination with label dose of pembrolizumab.
Part 2 is phase II design of APG-115 at recommended phase 2 dose (RP2D) in combination with
pembrolizumab in patients with programmed cell death protein 1 (PD-1)/programmed death-ligand
1 (PD-L1) refractory/relapsed melanoma or NSCLC, lung adenocarcinoma with STK11 mutation,
solid tumors with P53 WT and ATM mutation, P53 WT and MDM2 amplification liposarcomas,
PD-1/PD-L1 refractory/relapsed urothelial carcinoma without FGFR translocation mutation, and
MPNST.